250 related articles for article (PubMed ID: 31129024)
1. Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project.
Rojas Rojas T; Di Beo V; Delorme J; Barre T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B; Marcellin F
Int J Drug Policy; 2019 Oct; 72():61-68. PubMed ID: 31129024
[TBL] [Abstract][Full Text] [Related]
2. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
Barré T; Marcellin F; Di Beo V; Delorme J; Rojas Rojas T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B
Addiction; 2020 Mar; 115(3):573-582. PubMed ID: 31595554
[TBL] [Abstract][Full Text] [Related]
3. Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study).
Rolland B; Lions C; Di Beo V; Carrieri P; Authier N; Barré T; Delorme J; Mathurin P; Bailly F; Protopopescu C; Marcellin F
Harm Reduct J; 2022 Oct; 19(1):119. PubMed ID: 36303159
[TBL] [Abstract][Full Text] [Related]
4. Transitioning from interferon-based to direct antiviral treatment options: A potential shift in barriers and facilitators of treatment initiation among people who use drugs?
Makarenko I; Artenie A; Hoj S; Minoyan N; Jacka B; Zang G; Barlett G; Jutras-Aswad D; Martel-Laferriere V; Bruneau J
Int J Drug Policy; 2019 Oct; 72():69-76. PubMed ID: 31010749
[TBL] [Abstract][Full Text] [Related]
5. High hepatitis C treatment uptake among people with recent drug dependence in New South Wales, Australia.
Valerio H; Alavi M; Law M; Tillakeratne S; Amin J; Janjua NZ; Krajden M; George J; Matthews GV; Hajarizadeh B; Degenhardt L; Grebely J; Dore GJ
J Hepatol; 2021 Feb; 74(2):293-302. PubMed ID: 32931879
[TBL] [Abstract][Full Text] [Related]
6. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017.
Aas CF; Vold JH; Skurtveit S; Odsbu I; Chalabianloo F; Lim AG; Johansson KA; Fadnes LT
Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):44. PubMed ID: 32605625
[TBL] [Abstract][Full Text] [Related]
7. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
[TBL] [Abstract][Full Text] [Related]
8. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
[TBL] [Abstract][Full Text] [Related]
9. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
[TBL] [Abstract][Full Text] [Related]
10. Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?
Panagiotoglou D; Krebs E; Min JE; Olding M; Ahamad K; Ti L; Montaner JSG; Nosyk B
Int J Drug Policy; 2017 Sep; 47():169-176. PubMed ID: 28578865
[TBL] [Abstract][Full Text] [Related]
11. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period?
Jain MK; Thamer M; Therapondos G; Shiffman ML; Kshirsagar O; Clark C; Wong RJ
Hepatology; 2019 Jan; 69(1):51-63. PubMed ID: 30019478
[TBL] [Abstract][Full Text] [Related]
12. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP;
PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
[TBL] [Abstract][Full Text] [Related]
14. Racial/Ethnic and Socioeconomic Disparities in Use of Direct-Acting Antivirals Among Medicare Beneficiaries with Chronic Hepatitis C, 2014-2016.
Jung J; Du P; Feldman R; Kong L; Riley T
J Manag Care Spec Pharm; 2019 Nov; 25(11):1236-1242. PubMed ID: 31663464
[TBL] [Abstract][Full Text] [Related]
15. Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study.
Gomes T; Campbell TJ; Martins D; Paterson JM; Robertson L; Juurlink DN; Mamdani M; Glazier RH
PLoS Med; 2021 Jun; 18(6):e1003631. PubMed ID: 34061846
[TBL] [Abstract][Full Text] [Related]
16. High HCV cure rates for people who use drugs treated with direct acting antiviral therapy at an urban primary care clinic.
Norton BL; Fleming J; Bachhuber MA; Steinman M; DeLuca J; Cunningham CO; Johnson N; Laraque F; Litwin AH
Int J Drug Policy; 2017 Sep; 47():196-201. PubMed ID: 28811158
[TBL] [Abstract][Full Text] [Related]
17. Autoantibodies to cytoplasmic rods and rings in patients with hepatitis C virus infection treated with direct-acting antivirals: The role of prior treatment with interferon plus ribavirin.
Alsius M; Ferri MJ; Buxó M; López C; Serra I; Queralt X; Acero D
Gastroenterol Hepatol; 2019 Feb; 42(2):82-89. PubMed ID: 30446175
[TBL] [Abstract][Full Text] [Related]
18. Acute cellular rejection in hepatitis C recipients following liver transplantation in the era of direct-acting antivirals: chronological analysis of the United Network for Organ Sharing database.
Tanaka T; Voigt MD
J Hepatobiliary Pancreat Sci; 2019 Sep; 26(9):393-400. PubMed ID: 31211912
[TBL] [Abstract][Full Text] [Related]
19. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
Butler K; Larney S; Day CA; Burns L
Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
[TBL] [Abstract][Full Text] [Related]
20. The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
Jiang X; Song HJ; Wang W; Henry L; Childs-Kean LM; Re VL; Park H
J Manag Care Spec Pharm; 2021 Jul; 27(7):873-881. PubMed ID: 34185563
[No Abstract] [Full Text] [Related]
[Next] [New Search]
